Starpharma Holdings Limited (ASX:SPL)

Jackie Fairley
CEO
Market Cap (AUD): 302.25M
Sector: Health Care
Last Trade (AUD): 0.7 +0 (+0%)
Tab Bar

1. About

Starpharma Holdings Limited (ASX:SPL) is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharmas underlying technology is built around dendrimers a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses.  Starpharma has two core development programs: VivaGel portfolio and DEP drug delivery with the Company developing several products internally and others via commercial partnerships.

VivaGel

Starpharmas womens health product - VivaGel BV is based on SPL7013, astodrimer sodium, a proprietary dendrimer. VivaGel BV for bacterial vaginosis (BV), is available for sale under the brand names Betafem BV Gel (UK), Betadine BVTM (Europe), BetadineTM BV Gel (Asia) and Fleurstat BVgel (Australia & NZ) and a new drug application has been submitted to the US FDA. Starpharma has licensed the sales and marketing of VivaGel BV to ITF Pharma for the US; Mundipharma for Europe, Russia, CIS, Asia, the Middle East, Africa and Latin America; and to Aspen Pharmacare for Australia and New Zealand. Starpharma also has licence agreements to market the VivaGel condom (an antiviral condom which includes VivaGel in the lubricant) in several regions, including Australia, Europe, Canada, China and Japan (Okamoto). The VivaGel condom has been launched in Japan under Okamotos 003 brand, and in Australia and Canada under the LifeStyles Dual Protect brand. The VivaGel condom is approved in Europe.

DEP

Dendrimer Enhanced Product: Starpharmas DEP drug delivery platform has demonstrated reproducible preclinical benefits across multiple internal and partnered DEP programs, including improved efficacy, safety and survival. Starpharma has three internal DEP products DEP docetaxel, DEP cabazitaxel and DEP irinotecan - in clinical development in patients with solid tumours. Starpharmas partnered DEP programs include a multiproduct DEP licence with AstraZeneca, which involves the development and commercialisation of two novel oncology compounds, with potential to add more. In June 2019 Starpharma signed a Development and Option agreement with AstraZeneca for a DEP version of one of AstraZenecas major marketed oncology medicines.

Founded in 1996, Starpharma listed on the Australian Securities Exchange in 2000 (ASX:SPL). Starpharma securities also trade in the US under the American Depository Receipts (ADR) program, and are listed on the OCTQX platform (OTCQX:SPHRY).

2. Business model

3. Strategy

4. Markets

5. Competition

6. History

7. Team

8. Financials

9. Risk